Gapping down
In reaction to earnings/guidance:
- CANO -43.2% (also provides update on strategic actions, including a possible sale; plans to exit some ops; workforce reduction; substantial doubt about ability to continue as a "going concern"; also to delay 10-Q filing), MAXN -25.7% (also chooses Albuquerque for its first US manufacturing expansion), VTYX -6.1%, OABI -4.3%, ARLO -3.2%, ONTO -3%, VIAV -2.5%, TARS -2.4%, ATGE -2.1%, EPSN -1.1%, HIVE -0.9%
Other news:
- AVAL -8.3% (announced resolutions of previously disclosed investigations by the DOJ and SEC related to the construction of a toll road in Colombia by a joint venture)
- VLD -6.6% (convertible notes offeing)
- OPTN -5.6% (files $200 mln mixed shelf securities offering)
- CDNA -3.9% (comments on issuance of proposed LCD for Molecular Testing for Solid Allograft Rejection)
- AKBA -3.4% (to delay 10-Q filing; also reaffirms guidance)
- BZH -3% (files mixed shelf securities offering)
- SRG -2.2% (to delay 10-Q filing)
- MELI -2% (names new CFO)
- FHTX -2% (MRK terminates Research Collaboration and Exclusive License Agreement with FHTX)
Analyst comments:
- OLPX -3.1% (downgraded to Hold from Buy at Canaccord Genuity)
- SEE -1.7% (downgraded to Neutral from Buy at UBS)
- SWK -1.4% (downgraded to Underperform from Peer Perform at Wolfe Research)
- HTBK -1.3% (downgraded to Equal-Weight from Overweight at Stephens)
- VTR -1.1% (downgraded to Neutral from Buy at BofA Securities)